Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217) is a long-acting glucagon-like peptide 1 (GLP-1) analogue and agonist of the GLP-1 receptor. It has potential therapeutic efficacy for type 2 diabetes mellitus (T2DM).